Company Overview
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Why Investors Should Care
Trades at a P/E of 20.6, below the sector median of 25.4.
Operating margin of 22.9% supports profitability.
Carries low leverage with a debt-to-equity ratio of 0.35.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $9.89B (+2.2% YoY); net profit $1.29B.
- Trailing 12 Months Year-on-year growth — revenue +1.9%, earnings +31.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 6.5%, profit CAGR 4.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 6.52% |
| 1 Year: | 1.90% |
Compounded Profit Growth
| 5 Years: | 4.00% |
| 1 Year: | 31.10% |
Stock Price Performance
| 1 Year: | +44.20% |
| 6 Months: | +2.31% |
| 3 Months: | +8.83% |
| 1 Month: | -4.01% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)42.42 · Neutral
P/E of 20.64 is below the sector median of 25.41 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BIIB Biogen Inc. NDXSPX | 191.95 | 20.64 | $28.34B | 0.00% | 10.89% | 7.70% | 6.52% | 4.00% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.56B | 2.59B | 2.78B | 2.84B | 2.73B | 2.89B | 2.96B | 2.87B | 2.81B | 3.08B | 3.08B | 3.31B | 3.13B | 3.36B | 3.44B | 3.53B | 3.49B | 3.62B | 3.60B | 3.67B | 3.53B | 3.68B | 3.38B | 2.85B | 2.69B | 2.77B | 2.78B | 2.53B | 2.59B | 2.51B | 2.46B | 2.46B | 2.53B | 2.29B | 2.46B | 2.47B | 2.43B | 2.65B | 2.53B | 2.48B |
| Gross Profit | 2.24B | 2.31B | 2.47B | 2.51B | 2.41B | 2.52B | 2.54B | 2.49B | 2.43B | 2.71B | 2.71B | 2.80B | 2.69B | 2.94B | 2.98B | 3.04B | 2.89B | 3.14B | 3.17B | 3.22B | 3.08B | 3.27B | 2.93B | 2.36B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | 1.12B | 1.23B | 1.37B | - | 1.38B | 1.46B | 1.43B | - | 1.02B | 1.20B | 1.65B | - | 1.53B | 1.21B | 1.70B | - | 1.50B | 1.96B | 1.81B | - | 1.82B | 1.97B | 1.09B | - | 973.90M | 485.70M | 794.00M | 610.70M | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | 822.50M | 927.30M | 965.60M | 831.60M | 970.90M | 1.05B | 1.03B | 649.20M | 747.60M | 862.80M | 1.23B | -297.40M | 1.17B | 866.60M | 1.44B | 946.80M | 1.41B | 1.49B | 1.55B | 1.44B | 1.40B | 1.54B | 701.50M | 357.90M | 410.20M | 448.50M | 329.20M | 303.80M | 1.06B | 1.13B | 387.90M | 591.60M | -68.10M | 393.40M | 583.60M | 388.50M | 240.50M | 634.80M | 466.50M | 319.50M |
| Diluted EPS | 3.49 | 3.93 | 4.15 | 3.77 | 4.43 | 4.79 | 4.71 | 2.99 | 3.46 | 4.07 | 5.79 | -1.40 | 5.54 | 4.18 | 7.15 | 4.73 | 7.15 | 7.85 | 8.39 | 8.08 | 8.08 | 9.59 | 4.46 | 2.32 | 2.69 | 2.99 | 2.22 | 2.06 | 7.24 | 7.84 | 2.67 | 4.07 | -0.47 | 2.70 | 4.00 | 2.66 | 1.64 | 4.33 | 3.17 | 2.15 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.17B | 4.10B | 4.38B | 4.72B | 5.05B | 5.52B | 6.93B | 9.70B | 10.76B | 11.45B | 12.27B | 13.45B | 14.38B | 13.44B | 10.98B | 10.17B | 9.84B | 9.68B | 9.89B |
| Gross Profit | - | - | 4.00B | 4.32B | 4.58B | 4.97B | 6.07B | 8.53B | 9.52B | 9.97B | 10.64B | 11.64B | 12.42B | 11.64B | - | - | - | - | - |
| Operating Income | 779.77M | 1.21B | 1.30B | 1.25B | 1.72B | 1.86B | 2.52B | 3.97B | 4.89B | 5.15B | 5.35B | 5.89B | 7.04B | 4.55B | 2.84B | - | - | - | - |
| Net Income | 638.17M | 783.17M | 970.13M | 1.01B | 1.23B | 1.38B | 1.86B | 2.93B | 3.55B | 3.70B | 2.54B | 4.43B | 5.89B | 4.00B | 1.56B | 3.05B | 1.16B | 1.63B | 1.29B |
| Diluted EPS | 1.99 | 2.65 | 3.35 | 3.94 | 5.04 | 5.76 | 7.81 | 12.37 | 15.34 | 16.93 | 11.92 | 21.58 | 31.42 | 24.80 | 10.40 | 20.87 | 7.97 | 11.18 | 8.79 |
| R&D Expense | 925.16M | 1.07B | 1.28B | 1.25B | 1.22B | 1.33B | - | - | - | - | - | - | - | - | - | - | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 8.48B | 8.55B | 8.09B | 9.05B | 10.13B | 11.86B | 14.31B | 19.50B | 22.88B | 23.65B | 25.29B | 27.23B | 24.62B | - | 24.55B | 26.84B | 28.05B | 29.44B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.79B | 6.86B | 7.46B | 8.97B |
| Cash & Equivalents | 661.38M | 659.66M | 622.38M | 581.89M | 759.60M | 514.54M | 570.70M | 602.60M | 1.20B | 1.31B | 2.33B | 1.57B | 1.22B | 2.91B | - | - | 3.42B | 1.05B | 2.38B | 3.01B |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.34B | 2.53B | 2.46B | 2.17B |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.14B | 2.10B | 1.87B | 1.87B |
| Total Liabilities | - | - | 2.65B | 2.29B | 2.64B | 2.62B | 3.17B | 3.24B | 3.50B | 10.13B | 10.75B | 11.05B | 12.26B | 13.90B | 13.93B | - | 11.17B | 12.05B | 11.33B | 11.18B |
| Current Liabilities | - | - | 923.22M | 714.94M | 1.05B | 912.89M | 1.66B | 1.76B | 2.22B | 2.58B | 3.42B | 3.37B | 3.30B | 4.86B | 3.74B | - | 3.27B | 3.43B | 5.53B | 3.35B |
| Long Term Debt | - | - | - | - | 1.04B | 1.02B | 687.40M | 592.43M | 580.30M | 6.52B | 6.51B | 5.93B | 5.94B | 4.46B | 7.43B | - | 6.28B | 6.79B | 4.55B | 6.29B |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.61B | 7.34B | 6.63B | 6.58B |
| Total Equity | 7.16B | 5.55B | 5.81B | 6.22B | 5.40B | 6.43B | 6.96B | 8.62B | 10.81B | 9.37B | 12.14B | 12.61B | 13.04B | 13.34B | 10.70B | - | 13.40B | 14.80B | 16.72B | 18.26B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 167.80M | 168.70M | 169.52M | 170.60M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 1.02B | 1.56B | 1.07B | 1.62B | 1.73B | 1.88B | 2.35B | 2.94B | 3.92B | 4.59B | 4.55B | 6.19B | 7.08B | 4.23B | 3.64B | 1.38B | 1.55B | 2.88B | 2.20B |
| Investing Cash Flow | -286.57M | -365.87M | -395.03M | 345.32M | -1.65B | -950.34M | -1.60B | -1.54B | -4.55B | -2.48B | -2.96B | -2.05B | 470.50M | -608.60M | -563.70M | 1.58B | -4.10B | -799.20M | -1.37B |
| Financing Cash Flow | -733.34M | -1.23B | -724.15M | -1.78B | -319.86M | -877.48M | -716.50M | -755.90M | 783.10M | -1.05B | -2.38B | -4.47B | -5.86B | -5.27B | -2.09B | -1.75B | 149.30M | -683.50M | -301.90M |
| Capital Expenditure | -284.11M | -275.95M | -165.65M | -173.06M | -208.02M | -254.55M | -246.30M | -287.80M | -643.00M | -616.10M | -867.40M | -770.60M | -514.50M | -424.80M | -258.10M | -240.30M | -277.00M | -153.70M | -153.80M |
| Free Cash Flow | 734.65M | 1.29B | 909.25M | 1.45B | 1.52B | 1.63B | 2.10B | 2.65B | 3.28B | 3.97B | 3.68B | 5.42B | 6.56B | 3.81B | 3.38B | 1.14B | 1.27B | 2.72B | 2.05B |
| Share Buybacks | 2.99B | 738.94M | 751.17M | 2.08B | 497.98M | 984.72M | 400.30M | 886.80M | 5.00B | 1.00B | 1.37B | 4.35B | 5.87B | 6.68B | 1.80B | 750.00M | 0 | 0 | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | 91.3% | 91.5% | 90.8% | 90.1% | 87.6% | 87.9% | 88.5% | 87.1% | 86.7% | 86.5% | 86.4% | 86.6% | - | - | - | - | - |
| Operating Margin % | 24.6% | 29.6% | 29.6% | 26.5% | 34.2% | 33.6% | 36.3% | 40.9% | 45.4% | 45.0% | 43.6% | 43.8% | 49.0% | 33.8% | 25.9% | - | - | - | - |
| Net Margin % | 20.1% | 19.1% | 22.2% | 21.3% | 24.5% | 25.0% | 26.9% | 30.2% | 33.0% | 32.3% | 20.7% | 32.9% | 41.0% | 29.8% | 14.2% | 29.9% | 11.8% | 16.9% | 13.1% |
| ROE % | 11.5% | 13.5% | 15.6% | 18.6% | 19.2% | 19.8% | 21.6% | 27.2% | 37.8% | 30.5% | 20.1% | 34.0% | 44.1% | 37.4% | - | 22.7% | 7.8% | 9.8% | 7.1% |
| ROCE % | - | 16.1% | 16.5% | 17.7% | 21.2% | 21.9% | 24.9% | 32.8% | 28.9% | 26.5% | 26.4% | 26.8% | 31.5% | 21.8% | - | - | - | - | - |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 10.82% | 15.97M | $3.41B |
| 2 | Primecap Management Company | 10.00% | 14.76M | $3.15B |
| 3 | FMR, LLC | 8.68% | 12.81M | $2.73B |
| 4 | Vanguard Capital Management LLC | 6.46% | 9.54M | $2.04B |
| 5 | State Street Corporation | 4.86% | 7.17M | $1.53B |
| 6 | Vanguard Portfolio Management LLC | 4.42% | 6.53M | $1.39B |
| 7 | Geode Capital Management, LLC | 2.94% | 4.34M | $926.84M |
| 8 | Wellington Management Group, LLP | 2.01% | 2.96M | $632.10M |
| 9 | Morgan Stanley | 1.47% | 2.17M | $463.34M |
| 10 | JPMORGAN CHASE & CO | 1.37% | 2.02M | $430.28M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BIIB
Biogen (BIIB) Following Fresh Alzheimer’s Data Is The Upside Story Still Intact
Biogen (BIIB) is back in focus after fresh Alzheimer’s data, including new real world results for LEQEMBI and Phase 2 findings for tau targeting candidate diranersen, gave investors more information on the company’s neurology pipeline. See …
IBM, Goldman Sachs, SK Hynix, Micron, CrowdStrike, Biogen, and More Stocks That Explain Today’s Market
FEATURE The and the tech-heavy were up Tuesday, led by the resurgent artificial-intelligence trade, as investors responded to cooler-than-expected U.S. inflation data for June, a slew of bank earnings reports, and a profit warning from IBM…
Biogen Slumps As Alzheimer's Study Leaves 'More Questions Than Answers'
Biogen and Ionis said Tuesday their tau-targeting Alzheimer's treatment slowed cognitive decline by 26% over the course of 18 months.
Biogen Backs Alzheimer’s Tau Drug for Phase 3 Despite Trial Miss
Biogen (NASDAQ:BIIB) said data from its Phase 2 CELIA study of diranersen in early Alzheimer’s disease provide proof of concept for the tau-targeting therapy, despite the trial not meeting its primary endpoint of demonstrating a predefined …
BIIB Stock On Track For Worst Day In 2 Years After RBC Questions If Alzheimer’s Drug Benefits Will Replicate In Further Study
Biogen’s mid-stage trial of diranersen did not meet its main goal of showing a clear relationship between higher doses and better results.
Biogen’s Alzheimer’s Drug Leaves Questions Unanswered, and That’s a Problem
The presentation on Biogen’s experimental Alzheimer’s treatment at a medical meeting Tuesday was supposed to boost confidence in its drug’s prospects. Instead, Biogen stock is down 6%, to $197. Tuesday’s presentation on the drug diraner…
BIIB — Frequently Asked Questions
What is the current share price of Biogen Inc. (BIIB)?
As of 2026-07-14 21:23 PDT, Biogen Inc. (BIIB) trades at $191.95 on NasdaqGS. Its 52-week range is $122.68 to $216.63.
What is the market capitalisation of BIIB?
Biogen Inc. (BIIB) has a market capitalisation of $28.34B on NasdaqGS.
What is the P/E ratio of BIIB?
BIIB trades at a trailing price-to-earnings (P/E) ratio of 20.64. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 1.58.
What is the return on equity (ROE) of BIIB?
BIIB has a return on equity (ROE) of 7.70%. Its return on capital employed (ROCE) is 10.89%.
Is BIIB a good stock to buy?
This page provides a data-driven analysis of Biogen Inc. (BIIB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.